IMMUNIZATION OF MICE WITH ALLOGENEIC FIBROBLASTS GENETICALLY-MODIFIED FOR INTERLEUKIN-2-SECRETION AND EXPRESSION OF MELANOMA-ASSOCIATED ANTIGENS STIMULATE PREDETERMINED CLASSES OF ANTIMELANOMA EFFECTOR-CELLS

被引:17
作者
KIM, TS [1 ]
COHEN, EP [1 ]
机构
[1] UNIV ILLINOIS,COLL MED,DEPT MICROBIOL & IMMUNOL MC790,CHICAGO,IL 60612
来源
JOURNAL OF IMMUNOTHERAPY | 1994年 / 16卷 / 01期
关键词
B16; MELANOMA; ALLOGENEIC MAJOR HISTOCOMPATIBILITY COMPLEX; INTERLEUKIN-2; MELANOMA-ASSOCIATED ANTIGENS; GENE TRANSFER;
D O I
10.1097/00002371-199407000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunization of C57BL/6 mice (H-2(b)) with a mouse fibroblast cell-line of C3H origin (H-2(k)) genetically modified for interleukin-2 (IL-2)-secretion and the expression of melanoma-associated antigens (MAAs) (RLBA-IL-2 cells) resulted in a systemic anti-melanoma cellular immune response that led to a prolongation of survival of mice with established melanoma. Here we report certain of the effector cell-types activated for anti-melanoma immunity in mice immunized with the modified cells and, for comparison, the antimelanoma cell-types activated following immunization with IL-2-secreting, MAA-negative fibroblasts (LM-IL-2 cells) or with non-IL-2-secreting, MAA-positive fibroblasts (RLBA-ZipNeo cells). The data indicate that both Lyt-2.2(+) (CD8(+)) and natural killer/lymphokine-activated killer (NK/LAK) cells with anti-melanoma cytotoxicity were predominant in mice immunized with RLBA-IL-2 cells. NK/LAK cells alone were predominant in mice immunized with LM-IL-2 cells, and Lyt-2.2(+) cells were predominant in mice immunized with RLBA-ZipNeo cells. The involvement of L3T4(+) (CD4(+)) cells in the effector phase of the response was not detected in mice immunized with the genetically modified cells. Immunization of mice with both LM-IL-2 cells and RLBA-ZipNeo cells resulted in an anti-melanoma response of greater magnitude than was present in mice immunized with either cell-construct alone. It (w)as equivalent to the melanoma immunity in mice immunized with RLBA-IL-2 cells. These data indicate that the immunogenic properties of the modified cells determined the anti-melanoma effector cell-types and suggest that combination immunotherapy with cell-constructs that stimulate different classes of effector cells may be more effective in immune-mediated tumor regression than immunization with a construct that activates a single effector cell-type alone.
引用
收藏
页码:24 / 35
页数:12
相关论文
共 41 条
[1]   EXPRESSION OF MURINE INTERLEUKIN-7 IN A MURINE GLIOMA CELL-LINE RESULTS IN REDUCED TUMORIGENICITY INVIVO [J].
AOKI, T ;
TASHIRO, K ;
MIYATAKE, S ;
KINASHI, T ;
NAKANO, T ;
ODA, Y ;
KIKUCHI, H ;
HONJO, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) :3850-3854
[2]  
ASHER AL, 1991, J IMMUNOL, V146, P3227
[3]  
BARKER E, 1988, CANCER RES, V48, P4834
[4]  
BOTTAZZI B, 1992, J IMMUNOL, V148, P1280
[5]   GRANULOCYTE COLONY-STIMULATING FACTOR GENE-TRANSFER SUPPRESSES TUMORIGENICITY OF A MURINE ADENOCARCINOMA INVIVO [J].
COLOMBO, MP ;
FERRARI, G ;
STOPPACCIARO, A ;
PARENZA, M ;
RODOLFO, M ;
MAVILIO, F ;
PARMIANI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (04) :889-897
[6]  
DIALYNAS DP, 1983, J IMMUNOL, V131, P2445
[7]   REDUCED TUMORIGENICITY OF FIBROSARCOMAS WHICH CONSTITUTIVELY GENERATE IL-1-ALPHA EITHER SPONTANEOUSLY OR FOLLOWING IL-1-ALPHA GENE-TRANSFER [J].
DOUVDEVANI, A ;
HULEIHEL, M ;
ZOLLER, M ;
SEGAL, S ;
APTE, RN .
INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (05) :822-830
[8]   VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543
[9]   INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE [J].
FEARON, ER ;
PARDOLL, DM ;
ITAYA, T ;
GOLUMBEK, P ;
LEVITSKY, HI ;
SIMONS, JW ;
KARASUYAMA, H ;
VOGELSTEIN, B ;
FROST, P .
CELL, 1990, 60 (03) :397-403
[10]  
FERRANTINI M, 1993, CANCER RES, V53, P1107